Download Open eyes on research (English)

research&innovation
Open eyes on research
Latest trends confirm the pharmaceutical industry’s steady growth
T
he world of pharmaceutical
innovation is making a comeback in Italia: the excellence of “Made in Italy” in research
and production is gaining important
recognition. Euticals is fully grasping the opportunities offered by
the market: with its ‘critical mass’,
ie its very complex international
structure that is a rarity in Italia,
and an average turnover of 200
million euros, the Group is ready
to take on any challenge, measuring
up to the competition”. This is how
our interview with Gian Mario Baccalini, President of Euticals, leader
in the manufacture of active ingredients, begins. In fact, thanks to its
strong synergy with the fi nancial
world, Euticals represents a business that is nothing short of revo-
lutionary in the Italian entrepreneurial landscape, a true turning
point compared to the traditional,
national industrial fabric of Smes.
“Euticals can be considered a true
benchmark in terms of the quality,
safety and reliability of the drugs
it produces, especially when compared to certain competitors” the
President points out. But what are
the novelties that have characterised the past two years of Euticals?
“First of all, a new Ceo has joined
our company, Margalitt Fine, who
can boast a long and consolidated
experience in the fi eld. Together
we are following a strategic plan of
industrial reorganisation that aims
to maximise the efficiency of the
various factories of Euticals according to the different technological
know-how and structures of fi xed
and variable costs, to achieve a more equitable and fair distribution of
the various product mixes”. The Euticals Group has several manufacturing sites: two in France, one in
Germany, one in the United States
and six in Italia: the most substantial investments will involve the factories of Origgio and Rozzano. Euticals has also streamlined the R&d
division, targeting to the sectors of
Custom Synthesis and Cmo (Contract Manufacturing Operations):
“The bulk of research is focused
on the development of new active
ingredients and drugs commissioned to us by multinationals. Their
decision to entrust this outsourced
activity to our company is the product of our established know-how
and reliability in delivering results
that an international group as ours
is able to guarantee”, says Baccalini. In the sector of Custom Synthesis, Euticals has grown by 20%,
but even the generic drug market
has shown a remarkably growing
trend. Thanks to the rationalisation of our marketing and manufacturing structure and of the R&d
division, Euticals can rightfully be
referred to as a true international
business. But the quantum leap was
also linked to the entry of investors
over the last few years - Mandarin
Capital Partners, Fondo Clessidra,
Private Equity Partners, Idea Capital, which together own 80% of
the share capital and to the acquisition of Poli Industria Chimica,
Archimica and Pharmintraco, and
30% of Tianma Tianji. “We now are
aiming at consolidating the acquisitions and completing the industrial
rationalisation process under way.
As mentioned at the beginning of
our interview, several ‘big pharma’
industries have turned to us in the
past two years, signing long-term
contracts as part of custom synthesis and Cmo, showing great interest
for our reliability and our quality
standards, which are by far much
higher than those offered by Asian
competitors. We therefore returned
to contractual dialogue, which is a
positive sign not only for the pharmaceutical industry, but for the
Italian economy more in general”.
Euticals’ goal is to become number
one in Italia and one of the best in
Europe for advanced technologies,
high quality, safety and production
efficiency. With this goal in mind,
the company has created a system
of strategic marketing that is clearly geared to the future. Euticals
is actually already looking to the
next stage in its process of growth,
thanks to a shared project that aims
for international affirmation. “The
further development of Euticals
will be rooted in the promotion of
essential values such as excellence and reliability towards our customers, in incisive marketing and
sales strategies, as well as the affirmation of a scientific soundness,
to establish the Euticals Group as a
leader in the field of Api and Pharma, capable of successfully pursuing continued growth. Euticals
already bases its current expansion
strategy on the most important players in the drug supply chain, seizing all possible opportunities offered by the market,” concludes
the President. The pharmaceutical
sector, which has always been a key
industry for the Italian economy, is
again a field of infinite possibilities
and potential, thanks to businesses
such as Euticals, which has left the
typically Italian dimension of Sme
to think “global” and not local, indispensable condition for a business
to establish itself on world markets.
-E.MARZORATI-
PH: ELISA CASANOVA
Gian Mario Baccalini
154
March 2015 PLATINUM
PLATINUM March 2015
155